via womenshealthency.com
Researchers at the Montreal Heart Institute announced today results showing that patients with cardiovascular disease and the appropriate genetic background benefit greatly from the new medication dalcetrapib, with a reduction of 39% in combined clinical outcomes including heart attacks, strokes, unstable angina, coronary revascularizations and cardiovascular deaths.
These patients also benefit from a reduction in the amount of atherosclerosis (thickened walls) in their vessels. The detailed results are published in the prestigious Journal Circulation Cardiovascular Genetics. This discovery may also pave the way for a new era in cardiovascular medicine, with personalized or precision drugs.
The team led by Drs Jean-Claude Tardif and Marie-Pierre Dubé performed the analysis of 5749 patients who received dalcetrapib or placebo and provided DNA in a clinical study. A strong association was discovered between the effects of dalcetrapib and a specific gene called ADCY9 (adenylate cyclase 9) on chromosome 16, particularly for a specific genetic variant (rs1967309). In patients with the genetic profile AA at rs1967309, there was a 39% reduction in the composite cardiovascular endpoint with dalcetrapib compared to placebo. Supporting evidence was also obtained from a second study, which showed that patients with the favourable genetic profile also benefited from a reduction in the thickness of their carotid artery walls with dalcetrapib.
“These results will lead to a genetics-guided clinical study in patients with the appropriate genetic background to allow review by health regulatory agencies and to provide personalized therapy with dalcetrapib. It also offers great hope for precision treatments for patients with cardiovascular diseases and for curbing atherosclerosis, the first cause of mortality in the world” said lead investigator Jean-Claude Tardif MD, director of the Research Center at the Montreal Heart Institute and professor of medicine at the University of Montreal.
Read more: A World First – Discovery of a personalized therapy for cardiovascular disease
The Latest on: Therapy for cardiovascular disease
via Google News
The Latest on: Therapy for cardiovascular disease
- New discovery uncovers secret switch that could revolutionize heart attack treatmenton April 8, 2021 at 11:01 am
Scientists at the Victor Chang Cardiac Research Institute in Sydney have discovered a critical new gene that it is hoped could help human hearts repair damaged heart muscle after a heart attack.
- Astonishing Secret Switch Discovered That Could Revolutionize Heart Attack Treatmenton April 8, 2021 at 11:00 am
Scientists at the Victor Chang Cardiac Research Institute in Sydney have discovered a critical new gene that it is hoped could help human hearts repair damaged heart muscle after a heart attack. Resea ...
- FibroGen Tumbles on Kidney Disease Treatment Data Clarificationon April 7, 2021 at 10:19 am
FibroGen shares are lower after the company clarified with the FDA certain disclosures it had made regarding its roxadustat kidney-disease treatment.
- Family of five-year-old with congenital heart disease appealing for public funds for treatmenton April 7, 2021 at 6:47 am
“I cannot bear to think that my son will no longer be with us just because I do not have enough money for his treatment, ” he said when interviewed here on Wednesday (April 7). Muhammad Irsyad was ...
- Study suggests that certain BP medications can reduce heart disease risk in people with HIVon April 6, 2021 at 3:38 pm
"Blood pressure and heart disease risk in patients who have HIV can be safely managed with first-line treatment of hypertension with ACEis, ARBs, CCBs and thiazide diuretics and may have added benefit ...
- Experimental Therapy For Parasitic Heart Disease – K777 – May Also Help Stop COVID-19on April 6, 2021 at 5:19 am
By blocking human enzyme cathepsin L, chemical inhibitor K777 reduces coronavirus' ability to infect cell lines; clinical trials are underway. James McKerrow, MD, PhD, dean of the Skaggs School of ...
- Achieving biomarker-based treatment target goals implies good prognosis for obese heart patientson April 5, 2021 at 4:25 am
In a recent study published in the Journal of the American Heart Association by University of Alabama at Birmingham researchers, findings indicate that among patients with heart failure, obesity is ...
- Experimental Therapy for Parasitic Heart Disease May Also Help Stop COVID-19on April 2, 2021 at 9:51 am
COVID-19 updates, including vaccine information, for our patients and visitors Learn More James McKerrow, MD, PhD, dean of the Skaggs School of Pharmacy and Pharmaceutical Sciences at University of ...
- Study explains the link between psoriasis treatment and cardiovascular diseaseson March 29, 2021 at 10:13 pm
Psoriasis is a chronic disease that causes patients to develop patches of dry, scaly, and itchy skin. It is an autoimmune disorder, which means that it arises from a person's immune system ...
- New Medtronic Implant a 'World First' for Congenital Heart Diseaseon March 26, 2021 at 11:14 am
FDA says the newly approved implant provides a less invasive option to treat pulmonary valve regurgitation for patients with a native or surgically-repaired right ventricular outflow tract.
via Bing News
